SCHEMBL10189406

SCHEMBL10189406

COc1ccc(-c2csnc2-c2cc(C)c(OC)c(OC)c2)cc1NC(=O)[C@H](N)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
NPSR1 Q6W5P4 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
AAK1 Q2M2I8 1/20 0.39
MAPT P10636 5/20 0.38
LMNA P02545 3/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
EIF2AK3 Q9NZJ5 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
GPR142 Q7Z601 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189408 1.00 ALDH1A1 (0.39) ALDH1A1NPSR1L3MBTL1AAK1MAPT
SCHEMBL10242332 0.95 ALDH1A1 (0.41) ALDH1A1NPSR1L3MBTL1AAK1MAPT
SCHEMBL10240332 0.95 ALDH1A1 (0.41) ALDH1A1NPSR1L3MBTL1AAK1MAPT
Hydrochloric Acid SCHEMBL624484 0.94 ALDH1A1 (0.40) ALDH1A1NPSR1L3MBTL1AAK1MAPT
SCHEMBL10189378 0.89 LMNA (0.38) ALDH1A1AAK1MAPTLMNARXFP1
SCHEMBL10189391 0.87 LMNA (0.39) ALDH1A1L3MBTL1AAK1MAPTLMNA
SCHEMBL10189390 0.87 LMNA (0.39) ALDH1A1L3MBTL1AAK1MAPTLMNA
SCHEMBL10189396 0.87 LMNA (0.37) ALDH1A1L3MBTL1AAK1MAPTLMNA
SCHEMBL10189395 0.87 LMNA (0.37) ALDH1A1L3MBTL1AAK1MAPTLMNA
SCHEMBL10189425 0.86 CIT (0.38) ALDH1A1AAK1LMNAGPR142

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885NPSR1 1837/4885L3MBTL1 3887/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885NPSR1 1837/4885L3MBTL1 3887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.